Balachandran Sreelakshmi Kokkatt, Iyer Krithika, Senthil Sowbarnika Arul, Ramalingam Akshaya Priya, Venkatachalam Sankar
Department of Anatomy, Dr. Arcot Lakshmanasamy Mudaliar Postgraduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India.
J Pharm Bioallied Sci. 2025 Jun;17(Suppl 2):S1877-S1881. doi: 10.4103/jpbs.jpbs_604_25. Epub 2025 Jun 18.
The inclusion of an anti-inflammatory agent shall be inevitable in a combinatorial approach toward treating spinal cord injury (SCI). However, the best among the commonly used anti-inflammatory agents, namely, steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and cyclooxygenases-2 (COX-2) selective NSAIDs is not known due to the lack of comparative studies.
It was intended to compare the efficacy of three classes of anti-inflammatory drugs in SCI by estimating the relevant cytokines.
Sprague Dawley rats subjected to contusion SCI were treated with methylprednisolone (steroid), or diclofenac (general COX-inhibitor), or meloxicam (selective COX-2 inhibitor). After three days of postlesion, the efficacy of the drugs was assessed by quantifying the levels of tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1) β, IL-6, IL-10, transforming growth factor-beta (TGF-β), and COX-2 through Western blotting.
The data were analyzed using one-way analysis of variance to determine statistical significance, and post-hoc analysis was performed using Tukey's test.
Pro-inflammatory cytokines (TNF-α, IL-6, and IL-1) upregulated by SCI were reduced only by meloxicam treatment. Upregulation of anti-inflammatory cytokines (IL-10, TGF-β) observed in injury was unaffected by methylprednisolone and diclofenac but was downregulated in the meloxicam group although statistically not significant.
By reducing the levels of pro-inflammatory cytokines and a mild increase in the levels of TGF-β, meloxicam outperforms the other two drugs tested. Reduced anti-inflammatory IL-10 levels in the meloxicam treatment were the only concern. Spinal inflammation may be more resilient and further studies are required to formulate a consistent anti-inflammatory therapy to treat contusion SCI.
在治疗脊髓损伤(SCI)的联合方法中,加入抗炎药物将是不可避免的。然而,由于缺乏比较研究,常用抗炎药物中,即类固醇、非甾体抗炎药(NSAIDs)和环氧化酶-2(COX-2)选择性NSAIDs中哪种是最佳药物尚不清楚。
通过评估相关细胞因子来比较三类抗炎药物在脊髓损伤中的疗效。
对遭受挫伤性脊髓损伤的Sprague Dawley大鼠分别用甲泼尼龙(类固醇)、双氯芬酸(一般COX抑制剂)或美洛昔康(选择性COX-2抑制剂)进行治疗。损伤后三天,通过蛋白质印迹法对肿瘤坏死因子-α(TNF-α)、白细胞介素-1(IL-1)β、IL-6、IL-10、转化生长因子-β(TGF-β)和COX-2的水平进行定量,以评估药物的疗效。
使用单因素方差分析对数据进行分析以确定统计学意义,并使用Tukey检验进行事后分析。
脊髓损伤上调的促炎细胞因子(TNF-α、IL-6和IL-1)仅在美洛昔康治疗后降低。损伤中观察到的抗炎细胞因子(IL-10、TGF-β)的上调不受甲泼尼龙和双氯芬酸的影响,但在美洛昔康组中下调,尽管在统计学上不显著。
通过降低促炎细胞因子水平并使TGF-β水平轻度升高,美洛昔康的表现优于其他两种受试药物。美洛昔康治疗中抗炎性IL-10水平降低是唯一需要关注的问题。脊髓炎症可能更具弹性,需要进一步研究以制定一致的抗炎疗法来治疗挫伤性脊髓损伤。